LIVANOVA PLC
LIVNNASDAQTrading Snapshot
- Day Range
- $79.88 – $81.92
- 52-Week Range
- $48.82 – $85.76
- Volume (shares)
- 550,582
- Avg Volume (shares)
- —
- Shares Outstanding
- 55.1M
- Next Earnings
- 2026-11-04
Fundamentals Snapshot
- Annual Revenue
- $1.39B
- Last Q Revenue
- $391M
- P/E Ratio
- 23.6
- P/S Ratio
- 3.0x
- EPS (TTM)
- $3.38
- Dividend Yield
- —
- Dilution (1yr)
- −0.4%
LIVANOVA PLC
LIVN
StockOtter · stockotter.spaceAbout LIVANOVA PLC
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Latest News & Updates
Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy
GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Neuromodulation: Technology at the Neural Interface has publ
LivaNova PLC $LIVN Shares Newly Acquired by Avidian Wealth Enterprises LLC
Avidian Wealth Enterprises LLC acquired a new position in LivaNova PLC (NASDAQ: LIVN) in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acq
Squarepoint Ops LLC Acquires Shares of 17,242 LivaNova PLC $LIVN
Squarepoint Ops LLC acquired a new position in shares of LivaNova PLC (NASDAQ: LIVN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund
LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
LivaNova PLC (LIVN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
LivaNova Director Sells 1,650 Shares for $131,500
The sale was valued at approximately $131,500. The shares traded were equal to 17% of the director's equity stake held directly before the filing.
LivaNova PLC $LIVN Stake Lessened by Bank of America Corp DE
Bank of America Corp DE cut its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 30.6% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 533,017 sha